Ignite Creation Date:
2025-12-26 @ 11:07 AM
Ignite Modification Date:
2026-01-13 @ 8:08 PM
Study NCT ID:
NCT04645212
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-08-07
First Post:
2020-11-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Sponsor:
Adverum Biotechnologies, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Choroidal Neovascularization | View |
| None | ADVM-022 | View |
| None | OPTIC Study | View |
| None | CNV | View |
| None | ADVM-022-01 | View |
| None | ADVM-022-07 | View |
| None | AAV.7m8 | View |
| None | Anti-VEGF therapy | View |
| None | Blindness | View |
| None | Gene therapy | View |
| None | Aflibercept (Eylea) | View |
| None | Age-Related Macular Degeneration | View |
| None | Wet Macular Degeneration | View |
| None | Retinal Degeneration | View |
| None | Retinal Diseases | View |
| None | Eye Diseases | View |
| None | AAV Vector | View |
| None | Adverum | View |
| None | wAMD | View |
| None | AMD | View |
| None | wet AMD | View |
| None | nAMD | View |
| None | OPTIC Extension | View |
| None | OPTIC-EXT | View |
| None | Long-term Follow Up | View |
| None | Long-term Extension | View |